Influence of young age at diagnosis and family history of breast or ovarian cancer on breast cancer outcomes in a population-based cohort study

Figueiredo, Jane C.; Ennis, Marguerite; Knight, Julia A.; McLaughlin, John; Hood, Nicky; O’Malley, Frances P.; Andrulis, Irene L.; Goodwin, Pamela J.

doi:10.1007/s10549-006-9433-3

Cited by 54 publications

(57 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast to others studies we could not demonstrate a difference in clinical, histopathological or treatment characteristics between those with one or more FDR vs. none [21][22][23][24]. In women with 2 FDR we noted a lower incidence of lymph node metastases, and less adjuvant systemic therapy seemed associated with a positive FH (p40.05).…”

Section: Discussioncontrasting

confidence: 99%

Long-term effects of first degree family history of breast cancer in young women: Recurrences and bilateral breast cancer

et al. 2015

View full text Add to dashboard Cite

Background. The aim of this study is to analyze the impact of first degree relative (FDR) of young breast cancer patients. Methods. Data were used from our prospective population-based cohort study which started in 1983. The family history (FH) was registered with regard to FDR: the presence or absence of invasive breast cancer in none vs. one or more FDRs at any age. Results. A total of 1109 women, 50 years with 1128 breast conserving treatments was seen. The incidence of FDR was 17.0% for one FDR and 3.2% 2 FDR. The three groups, none, 1 or 2 FDR, were comparable. The local failure rate is comparable for all three groups. Women with a positive FH and metachronous bilateral breast cancer (MBBC) showed a lower local failure (HR 0.2; 95% CI 0.05-0.8). A positive FH was an independent predictor for a better disease-specific survival (HR 0.6; 95% CI 0.4-0.9). Conclusion. A positive FH, based on FDR implies a better prognosis in relation to survival for young women treated with BCT. In contrast to no FH for FDR, MBBC in women with a positive FH was not associated with an increased risk of local recurrence.

show abstract

Section: Discussioncontrasting

confidence: 99%

Long-term effects of first degree family history of breast cancer in young women: Recurrences and bilateral breast cancer

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Nevertheless, overall survival is still poor in this group of young women. This is likely to be related to a more aggressive phenotype with less hormonally sensitive cancers (Figueiredo et al, 2007;Anders et al, 2008). The poor prognosis seems to particularly apply to breast cancer patients at age o35 years and is consistent between studies in the United Kingdom, North America and Asia (Nixon et al, 1994;Jmor et al, 2002;Han and Kang, 2010).…”

Section: Model Performancesmentioning

confidence: 52%

Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status

et al. 2010

View full text Add to dashboard Cite

BACKGROUND: There are relatively few articles addressing long-term follow-up in women with breast cancer at very young ages. METHODS: We have updated and extended our population-based analysis of breast cancer diagnosed at the age p30 years in Northwest England to include an extra 15 patients with mutation testing in BRCA1, BRCA2 and TP53, with 115 of 288 consecutive cases being tested. Kaplan -Meier curves were generated to assess overall survival, contralateral breast cancer and other second primaries. RESULTS: Survival analysis of all 288 patients showed poor overall survival, although this improved from a 15-year survival of only 46% in those diagnosed between 1980 and 1989 to 58% in those diagnosed between 1990 and 1997 (P ¼ 0.05). Contralateral breast cancer rates were at a steady rate of 0.6 per 1000, although the rates in mutation carriers were B2 per 1000. Altogether, 16 BRCA1, 9 BRCA2 and 6 TP53 mutations have now been found among the 115 cases on whom DNA analysis has been performed. BRCAPRO accurately predicted the number of carriers for BRCA1 and BRCA2 and was sensitive and specific at the 10 and 20% threshold, respectively. However, BRCAPRO did not seem to give any weight to DCIS, which accounted for two BRCA1 carriers and three TP53 carriers and overpredicted mutations at the high end of the spectrum, with only 6 of 11 (54%) with a 490% probability having identifiable BRCA1/2 mutations. INTERPRETATION: Rates of new primaries are predicted to some extent by mutation status. BRCAPRO is useful at determining those patients aged p30 years to be tested.

show abstract

“…In younger African-American women, risk was significantly higher in those with the GSTT1 null alleles. Breast cancer in young women, particularly those younger than 35 years, is associated with a poorer prognosis (56,57). The differences in tumor histopathology and patient prognosis may be related to the poor differentiation of tumors, their higher grade and the presence of mutations in tumor suppressor genes such as p53 (58,59).…”

Section: Discussionmentioning

confidence: 99%

Polymorphisms in CYP1B1, GSTM1, GSTT1 and GSTP1, and susceptibility to breast cancer

Emburgh

Hu²,

Levine³

et al. 2008

Oncol Rep

View full text Add to dashboard Cite

Polymorphisms in the cytochrome P450 1B1 (CYP1B1) and glutathione S-transferase (GST) drug metabolic enzymes, which are responsible for metabolic activation/detoxification of estrogen and environmental carcinogens, were analyzed for their association with breast cancer risk in 541 cases and 635 controls from a North Carolina population. Each polymorphism, altering the catalytic function of their respective enzymes, was analyzed in Caucasian and African-American women. As reported in previous studies, individual polymorphisms did not significantly impact breast cancer risk in either Caucasian or African-American women. However, African-American women exhibited a trend towards a protective effect when they had at least one CYP1B1 119S allele (OR=0.53; 95% CI=0.20-1.40) and increased risk for those women harboring at least one CYP1B1 432V allele (OR=5.52; 95% CI=0.50-61.37). Stratified analyses demonstrated significant interactions in younger (age ≤60) Caucasian women with the CYP1B1 119SS genotype (OR=3.09; 95% CI=1.22-7.84) and younger African-American women with the GSTT1 null genotype (OR=4.07; 95% CI=1.12-14.80). A notable trend was also found in Caucasian women with a history of smoking and at least one valine allele at GSTP1 114 (OR=2.12; 95% CI=1.02-4.41). In Caucasian women, the combined GSTP1 105IV/VV and CYP1B1 119AA genotypes resulted in a near 2-fold increase in risk (OR=1.96; 95% CI=1.04-3.72) and the three way combination of GSTP1 105IV/VV, CYP1B1 119AS/SS and GSTT1 null genotypes resulted in an

show abstract

Influence of young age at diagnosis and family history of breast or ovarian cancer on breast cancer outcomes in a population-based cohort study

Abstract: Women diagnosed with BC at age

Cited by 54 publications

References 51 publications

Long-term effects of first degree family history of breast cancer in young women: Recurrences and bilateral breast cancer

Long-term effects of first degree family history of breast cancer in young women: Recurrences and bilateral breast cancer

Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status

Polymorphisms in CYP1B1, GSTM1, GSTT1 and GSTP1, and susceptibility to breast cancer

Contact Info

Product

Resources

About